Our Immune Engaging TriNKETs® & Other Novel Immune Modulators
Dragonfly's Proprietary Platforms
Patient Need
For example, CAR T cell based treatments have offered some autoimmune disease and cancer patients remarkable therapeutic benefits, but challenges in manufacturing, costs and distribution make development challenging and leave many patients behind.
Dragonfly's Natural Killer (NK) cell-harnessing TriNKETs harness the body’s natural immune defenses to seek and destroy diseased cells across a broad range of indications – from autoimmune disease and cancers, to neurology and fibrosis.
Dragonfly's Cytokines are designed with an extended half life, offering greater exposure with less frequent dosing, and expand the therapeutic index of natural cytokines.
​​
Dragonfly’s drugs are designed to have distinct modes of action and favorable safety profiles, offering impactful and differentiated treatments with a broad therapeutic window in diseases where patient benefits can be considerable and available disease treatments are limited.
Dragonfly's TriNKETs® and Cytokines dramatically expand immunotherapy, providing more options for patients
Dragonfly’s TriNKETs® amplify the power of traditional immunotherapy by engaging both the adaptive and innate immune systems, directly and indirectly, with a single mechanism.
Our TriNKETs® potently stimulate both Natural Killer cells in the innate immune system, and CD8 T cells in the adaptive immune system, offering a distinctly powerful therapeutic agent with a compelling safety profile, in a single drug.
​
Both Dragonfly’s TriNKETs® and CYTOKINEs are designed to work combinatorily with a wide range of other I/O drugs, as well as with other traditional treatment approaches such as, in oncology, ADCs, chemotherapy and radiation.
​
Dragonfly’s TriNKETs® and CYTOKINEs have extraordinary CMC profiles that allow them to titre well, purify simply, concentrate easily and be stable under a wide range of conditions.